Respiratory syncytial virus infection in high risk groups, those with weak immune system, young infants and the elderly, can lead to lung and airway infections.
![Vaccine Developed By Novavax May Help Prevent Common Respiratory Viral Infection Vaccine Developed By Novavax May Help Prevent Common Respiratory Viral Infection](https://images.medindia.net/health-images/1200_1000/malaria-vaccine.jpg)
Wedbush analyst Heather Behanna estimated that an RSV vaccine represents a $1 billion opportunity in the United States and potentially double that worldwide.
The seasonal infection for most older healthy children and adults causes little more than a common cold but for high risk groups, such as those with weak immune system, young infants and the elderly, can lead to more serious results like lung and airway infections.
The vaccine developed by Novavax was similar to or better than a number of respiratory vaccines tested in the elderly. With this data, the company hopes to begin a late-stage 8,000-10,000 patient study in the elderly this year which coincides with the RSV season in the United States.
In a separate mid-stage trial in an attempt to jumpstart infant immunity, Novavax is also immunizing pregnant women. Data from this trial is expected later this quarter. The biotech is aiming for the regulator’s fast-track and/or breakthrough therapy pathway, potentially shortening its path towards approval.
MedImmune, now part of AstraZeneca Plc, developed a drug that prevents lung infections caused by RSV but not the RSV infection itself, though the virus was identified 60 years ago.
Advertisement
Dr. Pedro Piedra of the Baylor College of Medicine, who also serves on Novavax’s scientific advisory board says RSV kills fewer people than influenza. On an average, between 10,000 and 15,000 elderly Americans die from RSV, while 20,000-50,000 older adults succumb to the flu.
Advertisement
Source-Medindia